Empagliflozin-d4 (Synonyms: BI 10773-d4) |
| Catalog No.GC47289 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Empagliflozin-d4 contains four deuterium atoms and is intended for use as an internal standard for the quantification of empagliflozin by GC- or LC-MS. Empagliflozin is a potent SGLT2 inhibitor (IC50 = 3.1 nM) that demonstrates a high degree of selectivity (>2,500-fold) over SGLT1, 4, 5, and 6.1 In clinical trials of patients with type 2 diabetes, formulations containing empagliflozin lowered fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids.2
1.Grempler, R., Thomas, L., Eckhardt, M., et al.Empagliflozin, a novel selective sodium glucose contransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes. Metab.14(1)83-90(2012) 2.Ndefo, U.A., Anidiobi, N.O., Basheer, E., et al.Empagliflozin (Jardiance): A novel SGLT2 inhibitor for the treatment of type-2 diabetesP.T.40(6)364-368(2015)
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *